Getting The Deal Through logo
Getting The Deal Through

ABA Life Sciences Conference: international perspectives on drug pricing (part 2)

Pharma - Features – 17 July 2018

The American Bar Association’s Section of International Law hosted its 2018 Life Sciences Conference in Copenhagen last month, including, among other sessions, a detailed panel discussion of drug pricing practices around the world.

US appeals court finds Jazz Pharma drug database patents obvious

Pharma - News – 17 July 2018

The Federal Circuit Court of Appeals has upheld a series of the decisions by the US Patent and Trademark Office appeals board, which found that patents relating to a distribution and tracking system for a “sensitive” drug owned by Dublin-headquartered Jazz Pharmaceuticals were invalid as obvious.

Greece fines GSK in 20-year parallel imports case

Pharma - News – 17 July 2018

Greece’s competition watchdog has fined GlaxoSmithKline more than €4 million for restricting its supply of two drugs to the country’s wholesalers, ending its second investigation of the conduct.

The PLN Round-up (17 July)

Pharma - The Round-up – 17 July 2018

News in brief from around the world…This week Novartis has rebutted a US Senate report on its interactions with Donald Trump’s former lawyer and two UK pharma bodies have made a positive assessment of the UK government’s Brexit White Paper.

ABA Life Sciences Conference: international perspectives on drug pricing (part 1)

Pharma - Features – 10 July 2018

Drug pricing is a “pivotal point” for the pharmaceuticals industry, where the high cost of innovation often comes into conflict with the political drive to keep prices down, according to an array of international speakers who offered local snapshots of recent developments at a conference held by the American Bar Association’s Section of International Law in Copenhagen last month.

King & Spalding recruits two from Paul Hastings in New York

Pharma - News – 10 July 2018

Pharma and biotechnology disputes specialists Gerald Flattmann and Evan Diamond have left Paul Hastings to join King & Spalding in New York, where Flattmann will serve as global chair of the firm’s life sciences patent litigation practice.

Follow Getting the Deal Through for the latest updates on law and regulation worldwide

Follow us on LinkedIn